Innovation in bioprocess strategies are enabled by new technologies. 3M™ advanced materials platforms and bioprocess expertise are used to enable process intensification and single use transition through creation of high-performance smart unit operations. In this session we look at how the interface between materials technology and bioprocessing is used to define and to accelerate key trends in the industry.

Key Take-Aways:

• Materials science drives innovation in bioprocessing
• Process compression is enabled by smarter unit operations
• Next generation of bioprocessing requires a step change in technology

Elucidating the value of process intensification using computational modeling.

Key Take-Aways:

• High product recovery across unit operations facilitate process intensification
• Performance of unit operations directly affects efficiency of the process
• Single use process transition increases flexibility and productivity

Panel Discussion: Designing Efficient and Economical Processes for Futures

What’s next in biopharmaceutical manufacturing? In this session, we will discuss key trends in biomanufacturing and what enables them. Acceleration of process development and characterization through digital and PAT technologies. Transition to column free processing. Tacking challenges in manufacturing of emerging modalities in cell and gene therapy. In addition, we uncover how advanced process technology solutions enable new bioprocess strategies.

Key Take-Aways:

• Process technology trends for wide range of modalities Gene to Protein
• Ensuring very high performance and robust unit operations leveraging technologies and digital
• Strategic alignment of digital transformation in development with manufacturing objectives can accelerate digital success

Key Take-Aways:

• Process technologies for wide range of modalities Gene to Protein
• Transition to high performance and robust unit operations across all modalities
• Design new process platform for mAb manufacturing

Never have outside forces driven therapeutic antibody (mAb) development as in today’s environment. Contract Development and Manufacturing Organizations (CDMOs) and biotech/pharmaceutical companies face pressures of reduced timelines, higher mAb titers, new modalities, cost-reduction, and regulatory oversight.

These forces are triggering re-evaluation of the standard mAb purification platform for clarification, capture, polishing and formulation. Today’s presentation will focus on solutions addressing the mounting pressures including combining unit operations, designing alternatives to standard column steps and identifying new capture and polishing media.

Panel Discussion: Biopharma for the Future!

How 3M responded to the COVID-19 pandemic to help enable production of life-saving vaccines and therapeutics amidst unprecedented demand

How are strategic partners helping Biopharma to re-align their manufacturing strategies for 2021 and beyond? In this session, discover 3Ms organization wide response to the pandemic to prepare biopharmaceutical and other industries to succeed in post pandemic environment.

3Ms Commitment is to be Improving Our Business, Our Planet, and Every Life.

3M has a long-standing commitment to sustainability. It anchors purpose-driven innovation in our products, manufacturing processes and new technologies—and we’re always trying to do more. One of our key strategies for advancing sustainability is the Sustainability Value Commitment, which requires every new product—including the 3M™ Polisher ST—to demonstrate how it drives impact for the greater good.

Key Take-Aways:

• How business responded to pandemic
• Lessons learned from COVID-19
• Sustainability imperative for biopharmaceutical companies to face the future
• 3Ms commitment to sustainability

Panel Discussion: Learning From 2020 Sustainability Imperatives for Biopharma and is Biopharma Supply Chain Model is Ready to Face the Future?